Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Answer


    Core claim (paper): RNF183 is upregulated in inflamed IBD colon tissue and promotes intestinal inflammation by enhancing ubiquitination/degradation of IκBα, activating NF-κB; miR-7 downregulates RNF183 and counteracts this pathway.
    Evidence in the provided full text includes human qRT-PCR/western/IHC, TNBS colitis mouse data, epithelial-cell NF-κB readouts, and mechanistic links via siRNA/plasmid ubiquitination assays plus miRNA mimic/inhibitor and luciferase 3′UTR reporter experiments.
    Skeptical note: several key mechanistic steps depend on overexpression/knockdown and on one ubiquitination substrate readout (IκBα) without orthogonal validation of ubiquitin linkage types or RNF183 activity dependence, so causal certainty is moderate rather than definitive.



     Long Answer


    Paper Review (Visual + Critical): RNF183 in IBD
    What the paper claims (pathway-level)
    • RNF183 is increased in inflamed colon in both CD and UC patients, localized to inflamed intestinal epithelial cells (qRT-PCR/western/IHC/quantification described).
    • RNF183 promotes inflammation via NF-κB by increasing IκBα ubiquitination/degradation, reducing IκBα levels and increasing NF-κB p65 activity/readouts in epithelial cells.
    • miR-7 is a negative regulator of RNF183 by targeting RNF183 3′UTR: miR-7 mimic decreases RNF183 mRNA/protein and suppresses RNF183 3′UTR reporter activity; inhibitor increases RNF183. miR-7 is downregulated in inflamed tissues, and miR-7 mimic ameliorates TNBS colitis phenotypes with corresponding RNF183/IκBα/NF-κB shifts.
    • Anti-TNF (infliximab / anti-TNF antibody) is reported to increase miR-7 and reduce RNF183 with downstream increases in IκBα and reductions in NF-κB-p65/RNF183 in treated specimens/mice.
    Visual: pathway map (from paper text)
    Diagram is a mechanistic consolidation of claims explicitly stated in the paper text (RNF183→IκBα ubiquitination/degradation→NF-κB→inflammation; miR-7 inhibits RNF183; TNF-α downregulates miR-7; anti-TNF shifts these relationships).
    Visual: RNF183–endoscopic activity correlation (IHC IOD)
    Extracted from the provided table in the paper text: correlation between RNF183 IHC IOD and endoscopic indicators.
    What kind of evidence this is (known vs inferred)
    Known from experiments in this paper (within-text claims):
    • RNF183 expression increases in inflamed colon (human cohorts + TNBS mouse model), and this is quantified by qRT-PCR/western/IHC as described.
    • RNF183 perturbation in intestinal epithelial contexts shifts NF-κB-related molecules (IκBα, NF-κB-p65) and inflammatory cytokines (IL-1β/IL-6/IL-8) after TNF-α stimulation as described.
    • RNF183 is reported to interact with IκBα and to modulate IκBα ubiquitination readouts in tagged-cell assays.
    • miR-7 directly targets RNF183 3′UTR in a luciferase reporter format, and miR-7 mimic/inhibitor alters RNF183 expression plus downstream IκBα/NF-κB pattern in cells and TNBS colitis phenotypes in vivo (as described).
    Inferred/causal claims (with uncertainties):
    • The paper asserts a functional E3-ubiquitin-ligase mechanism (RNF183→IκBα ubiquitination/degradation→NF-κB activation). However, the provided text does not specify ubiquitin linkage types or catalytic-dead RNF183 rescue in the mechanistic summary, which weakens activity specificity (causal certainty is therefore moderate).
    • The paper suggests feedback from NF-κB to RNF183 (NF-κB inhibitor reduces TNF-α-induced RNF183 mRNA). That is consistent with pathway crosstalk but remains indirect without identifying the exact transcriptional regulation mechanism in the provided text.
    Skimming tables (quick consistency checks)
    Cohort Index n r P
    CD CDEIS 125 0.192 0.032
    UC Mayo 123 0.627 <0.001
    Interpretation caution: correlation coefficients differ markedly (CD vs UC), which can reflect biology, measurement differences, or statistical/model choices; without the full distribution details, the practical strength is uncertain.
    Mechanistic plausibility (integrating known biology)

    The paper’s central logic—ubiquitin-dependent control of IκBα degradation enabling NF-κB activation—is broadly consistent with established NF-κB regulation models: IκBα degradation is a canonical route to NF-κB activation, and ubiquitin/proteasome pathways are a major way this occurs.

    Critically, the linkage and specificity of ubiquitination are not detailed in the provided text excerpt, so the work shows directionality (RNF183 perturbations correlate with IκBα ubiquitination/degradation and NF-κB readouts) but leaves mechanistic granularity open.

    Counterpoints & blind spots (skeptical checklist)
    • Substrate specificity: The main substrate focus is IκBα. NF-κB regulation is complex; without broader proteome/target mapping, alternative or additional RNF183 substrates remain plausible.
    • Activity-specific controls: Causal inference would be strengthened by RNF183 catalytic-dead rescue and by chain-type determination in the ubiquitination assay; these are not described in the provided excerpt.
    • Model generalizability: The in vivo model is TNBS-induced colitis and in vitro models are mainly cell lines; IBD in humans includes immunological and microbiome heterogeneity that may not match TNBS biology.
    • Biomarker vs mechanism: The paper reports serum RNF183 does not differ in active IBD vs controls, suggesting tissue-local biology rather than circulating biomarker utility. That is consistent with localization claims but also limits non-invasive translational claims.
    • miRNA off-target risk: miR-7 mimic/inhibitor can affect multiple targets. Direct rescue experiments (e.g., RNF183 re-expression resistant to miR-7) would make the miR-7→RNF183 causal chain more stringent. The provided excerpt emphasizes the RNF183 3′UTR reporter and expression changes, but does not describe full rescue.
    Bottom-line scientific assessment
    This paper builds a coherent miR-7 ↔ RNF183 ↔ IκBα/NF-κB mechanistic narrative using multiple experimental modalities across human tissue, epithelial-cell assays, and a TNBS colitis model. Confidence in the general direction (RNF183 promotes NF-κB-driven inflammation; miR-7 restrains RNF183) is moderate, while mechanistic certainty (chain topology/activity specificity; rescue against off-targets; broader substrate mapping) remains incomplete from the provided excerpt.


    Feedback:    

    Updated: March 27, 2026

     BGPT Paper Review


    Study Novelty

    50%

    Moderate novelty: it identifies RNF183 and miR-7 as a specific mechanistic axis in IBD, but it uses a common NF-κB/IκBα ubiquitination framework rather than introducing a wholly new class of regulatory mechanism.


    Scientific Quality

    70%

    Scientific quality is moderate-to-good due to multimodal evidence (human cohorts + TNBS model + mechanistic assays including interaction/ubiquitination and 3′UTR reporter). Skepticism remains because the provided excerpt does not show chain-type specificity, catalytic-dead RNF183 activity controls, or miR-7-resistant RNF183 rescue to rule out off-target miRNA effects.


    Study Generality

    60%

    Mechanism may generalize to inflammatory epithelial contexts where NF-κB/IκBα ubiquitination is regulated by RNF E3 ligases and miRNA feedback, but the specificity to RNF183/miR-7 in IBD and the use of TNBS/cell lines limit broad generalization.


    Study Usefulness

    70%

    Useful as a hypothesis generator and mechanistic framework linking miR-7/RNF183 to NF-κB via IκBα ubiquitination; moderate usefulness for translational biomarker development because serum RNF183 was reported not different.


    Study Reproducibility

    60%

    Many methods are described (qRT-PCR, western, IHC quantification by IOD, cell transfection/siRNA, immunoprecipitation, luciferase reporter, TNBS model endpoints). However, the excerpt does not include detailed dataset accession numbers or raw data availability statements, and some experimental details (e.g., ubiquitin linkage characterization) are not shown here.


    Explanatory Depth

    70%

    Mechanistic chain is fairly deep for a translational immunology paper (RNF183↔IκBα ubiquitination→NF-κB readouts; miR-7 directly targets RNF183 3′UTR; TNF-α modulates miR-7). Depth is reduced by missing ubiquitin chain topology and activity-specific rescue controls in the excerpt.


    🎁 Authors: Collect 123 Free Science Tokens (≈ $12.3 USD)

    Claim My Author Tokens

    Use for 30 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $12.3 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    It will extract the RNF183–IHC correlation values from the paper text, generate a publication-ready correlation plot, and output a compact table for reuse in lab notebooks.



     Hypothesis Graveyard


    A strongman alternative is that RNF183 upregulation is merely a correlated consequence of NF-κB activation (not a driver). It becomes less likely if RNF183 knockdown consistently reduces NF-κB activation/cytokines even when TNF-α stimulation is maintained, and if RNF183 is sufficient to restore NF-κB outputs when miR-7 is inhibited; the excerpt supports knockdown effects but lacks catalytic-dead/activity-specific sufficiency tests.


    Another alternative is that miR-7 effects on inflammation are mostly off-target (not mediated primarily through RNF183). This weakens if RNF183 re-expression (miR-7-resistant) restores the NF-κB/inflammation phenotype under miR-7 mimic; the excerpt demonstrates RNF183 3′UTR regulation and RNF183 expression changes but does not show full miR-7-resistant rescue, so off-target possibility remains open.

     Science Art


    Paper Review: E3 Ubiquitin ligase RNF183 Is a Novel Regulator in Inflammatory Bowel Disease Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending